Mathematical modeling of prostate cancer progression in response to androgen ablation therapy
- 21 November 2011
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 108 (49), 19701-19706
- https://doi.org/10.1073/pnas.1115750108
Abstract
Prostate cancer progression depends in part on the complex interactions between testosterone, its active metabolite DHT, and androgen receptors. In a metastatic setting, the first line of treatment is the elimination of testosterone. However, such interventions are not curative because cancer cells evolve via multiple mechanisms to a castrate-resistant state, allowing progression to a lethal outcome. It is hypothesized that administration of antiandrogen therapy in an intermittent, as opposed to continuous, manner may bestow improved disease control with fewer treatment-related toxicities. The present study develops a biochemically motivated mathematical model of antiandrogen therapy that can be tested prospectively as a predictive tool. The model includes “personalized” parameters, which address the heterogeneity in the predicted course of the disease under various androgen-deprivation schedules. Model simulations are able to capture a variety of clinically observed outcomes for “average” patient data under different intermittent schedules. The model predicts that in the absence of a competitive advantage of androgen-dependent cancer cells over castration-resistant cancer cells, intermittent scheduling can lead to more rapid treatment failure as compared to continuous treatment. However, increasing a competitive advantage for hormone-sensitive cells swings the balance in favor of intermittent scheduling, delaying the acquisition of genetic or epigenetic alterations empowering androgen resistance. Given the near universal prevalence of antiandrogen treatment failure in the absence of competing mortality, such modeling has the potential of developing into a useful tool for incorporation into clinical research trials and ultimately as a prognostic tool for individual patients.Keywords
This publication has 31 references indexed in Scilit:
- Abiraterone and Increased Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2011
- The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical modelBiology Direct, 2010
- Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916Journal of Clinical Oncology, 2009
- Establishing normal reference ranges for prostate volume change with age in the population‐based Krimpen‐study: Prediction of future prostate volume in individual menThe Prostate, 2007
- Estimates of the cancer incidence and mortality in Europe in 2006Annals of Oncology, 2007
- Rapid Androgen Cycling as Treatment for Patients with Prostate CancerClinical Cancer Research, 2006
- Mathematical model for the androgenic regulation of the prostate in intact and castrated adult male ratsAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- Androgen deprivation therapy for prostate cancer: Current status and future prospectsThe Prostate, 2004
- A mathematical model of prostate tumor growth and androgen-independent relapseDiscrete & Continuous Dynamical Systems - B, 2003
- Studies on Prostatic Cancer: I. The Effect of Castration, Of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the ProstateCA: A Cancer Journal for Clinicians, 1972